Company intelligence / Profile preview
Auron Therapeutics
Newton, Massachusetts, United Statesaurontx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Auron Therapeutics has received FDA clearance for its IND application and is initiating clinical development of AUTX-703, a novel KAT2A/B degrader, in hematological malignancies. The company has presented preclinical data showing AUTX-703 provides significant survival advantage in AML models. AUTX-703 has also been granted Fast Track Designation by the FDA for relapsed or refractory AML.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesDegraders
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Auron Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Auron Therapeutics.